Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5127]
News [14850]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Researchers uncover on/off switch for breast cancer metastasis
Researchers uncover on/off switch for breast cancer metastasis
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma
ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk...
ASH 2023: Patients with a common form of acute myeloid leukemia report better quality of life when treatment includes new drug quizartinib
ASH 2023: Patients with a common form of acute myeloid leukemia report better quality of life when treatment...
ASH 2023: Landscape for AML patients evolving rapidly as research discoveries advance new treatments
ASH 2023: Landscape for AML patients evolving rapidly as research discoveries advance new treatments
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
ASH 2023: Hodgkin lymphoma prognosis, biology tracked with circulating tumour DNA
ASH 2023: Hodgkin lymphoma prognosis, biology tracked with circulating tumour DNA
ASH 2023: New personalised therapy improves survival for patients with CLL leukaemia
ASH 2023: New personalised therapy improves survival for patients with CLL leukaemia
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
ASH 2023: New drug helps narrow racial survival disparity in patients with acute myeloid leukaemia
ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated
ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation